BioDrone Therapeutics Inc.
  • Home
  • About Us
  • More
    • Home
    • About Us
BioDrone Therapeutics Inc.
  • Home
  • About Us

Press Releases

MDimune Named as a Finalist in the Prestigious 2023 Edison Awards™

MDimune announces a collaboration with Hanyang University through the 3rd BioDrone™ Award

MDimune announces a collaboration with Hanyang University through the 3rd BioDrone™ Award

Feb 22, 2023  BioDrone™ next-generation drug delivery platform honored for excellence alongside other innovators and innovations in the Health, Medical & Biotech category 

Find out more

MDimune announces a collaboration with Hanyang University through the 3rd BioDrone™ Award

MDimune announces a collaboration with Hanyang University through the 3rd BioDrone™ Award

MDimune announces a collaboration with Hanyang University through the 3rd BioDrone™ Award

Jan 26, 2023  MDimune Inc. announced funding of two research projects focusing on next-generation drug delivery and novel therapeutics. 

Find out more

MDimune announced the development of the GMP manufacturing process CDVs in the latest publication

MDimune announced the development of the GMP manufacturing process CDVs in the latest publication

MDimune announced the development of the GMP manufacturing process CDVs in the latest publication

Jan 5, 2023   MDimune Inc. announced the publication of data in the Journal of Extracellular Biology showing the development of the Good Manufacturing Practice (GMP)-compliant manufacturing process of CDVs and their biological activities. 

Find out more

MDimune Inc. enters into a Research Collaboration Agreement with Australian National University

MDimune announced the development of the GMP manufacturing process CDVs in the latest publication

MDimune announced the development of the GMP manufacturing process CDVs in the latest publication

Dec 7, 2022   MDimune Inc. announced a research collaboration agreement with the Clear Vision Research Lab (CVR Lab) at the ANU, experts in retinal degenerations. 

Find out more

MDimune acquires IP and partners with Ewha Womans University Medical Center on IBD therapeutics

MDimune announced the development of the GMP manufacturing process CDVs in the latest publication

MDimune acquires IP and partners with Ewha Womans University Medical Center on IBD therapeutics

Nov 7, 2022  MDimune, Inc. announced a business agreement with EUMC and acquisition of IP from EUMC to develop therapeutics for inflammatory bowel diseases (IBD). 

Find out more

MDimune and SensoryCure announce a collaboration to develop therapeutics for hearing loss

MDimune and SensoryCure announce a collaboration to develop therapeutics for hearing loss

MDimune acquires IP and partners with Ewha Womans University Medical Center on IBD therapeutics

Oct 24, 2022   MDimune, Inc. enters into an MOU with SensoryCure to collaborate on the development of therapeutics for hearing loss .

Find out more

Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for cancer

MDimune and SensoryCure announce a collaboration to develop therapeutics for hearing loss

Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for cancer

Sep 15, 2022  Caravan Biologix and MDimune announced their collaboration to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers.

Find out more

MDimune is named as one of the Top 10 Biotech Startups in APAC - 2022

MDimune and SensoryCure announce a collaboration to develop therapeutics for hearing loss

Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for cancer

May 2022 A distinguished panel and the editorial board of Life Science Review APAC has selected a list of biotech startups.  MDimune: The Pioneer of Cell-Derived-Vesicle Therapeutics 

Find out more

MDimune signs research agreement with YiPSCELL to develop iPSC-based BioDrone® Therapeutics

MDimune’s 2021 BioDrone® Award Nominations: Research grant awarded to NUS pharmacy research team

MDimune signs research agreement with YiPSCELL to develop iPSC-based BioDrone® Therapeutics

Feb 28, 2022  MDimune has announced the joint research agreement with YiPSCELL to develop BioDrone® Platform therapeutics based on induced pluripotent stem cells (iPSCs). 

Find out more

PCI Biotech and MDimune announce research collaboration agreement

MDimune’s 2021 BioDrone® Award Nominations: Research grant awarded to NUS pharmacy research team

MDimune signs research agreement with YiPSCELL to develop iPSC-based BioDrone® Therapeutics

Jan 5, 2022  PCI (Oslo, Norway) and MDmune today announced a preclinical research collaboration that would offer several opportunities for future development. 

Find out more

MDimune’s 2021 BioDrone® Award Nominations: Research grant awarded to NUS pharmacy research team

MDimune’s 2021 BioDrone® Award Nominations: Research grant awarded to NUS pharmacy research team

MDimune’s 2021 BioDrone® Award Nominations: Research grant awarded to NUS pharmacy research team

Dec 28, 2021  Among participants, Assoc. Prof. Giorgia Pastorin’s BioNanoTechnology Research Group at the National University of Singapore’s Department of Pharmacy (NUS Pharmacy) was nominated as the finalist of the program. 

Find out more

MDimune pens FAF1 mRNA cancer drug deal with Kainos Medicine

PROKR1 delivery by CDVs restores the myogenic potential of Prokr1-deficient C2C12 myoblasts

MDimune’s 2021 BioDrone® Award Nominations: Research grant awarded to NUS pharmacy research team

Oct 29, 2021  MDimune and Kainos Medicine have inked a collaboration and possible licensing deal for cancer therapy development based on CDVs loaded with Fas-associated Factor 1 (FAF1) expressing mRNA or protein. 

Find out more

NeoCura and MDimune settle CDVs-mediated mRNA collaboration

PROKR1 delivery by CDVs restores the myogenic potential of Prokr1-deficient C2C12 myoblasts

PROKR1 delivery by CDVs restores the myogenic potential of Prokr1-deficient C2C12 myoblasts

Oct 22, 2021 NeoCura Bio-Medical Technology Co., Ltd, a leading AI-enabled RNA precision medicine company and MDimune Inc. have announced the signing of collaboration focused on mRNA delivery for oncological therapeutics.

Find out more

PROKR1 delivery by CDVs restores the myogenic potential of Prokr1-deficient C2C12 myoblasts

PROKR1 delivery by CDVs restores the myogenic potential of Prokr1-deficient C2C12 myoblasts

PROKR1 delivery by CDVs restores the myogenic potential of Prokr1-deficient C2C12 myoblasts

Sep 13, 2021  MDimune Inc., a leading cell-derived vesicles (CDVs) company in South Korea has announced the outcomes of the research collaboration with Prof. Joonghoon Park’s team at Seoul National University. 

Find out more

Mdimune Inc. announces research collaboration with the SNU for gene editing based on CDVs

Mdimune Inc. announces research collaboration with the SNU for gene editing based on CDVs

Mdimune Inc. announces research collaboration with the SNU for gene editing based on CDVs

Sep 9, 2021 This collaboration with top-ranked university in South Korea will revolutionize the delivery of gene editing nuclease packaged CDVs for precise delivery to cells which will enable gene correction, gene modification, knockout and gene addition at intended location.   

Find out more

Vect-Horus and MDimune collaborate to develop a novel approach to CNS drug delivery

Mdimune Inc. announces research collaboration with the SNU for gene editing based on CDVs

Mdimune Inc. announces research collaboration with the SNU for gene editing based on CDVs

Sep 7, 2021   MDimune Inc. and Vect-Horus are please to announce today the signing of a Research Collaboration Agreement. 

Find out more

MDimune is named as one of the world's seven leading companies In exosome research

Mdimune Inc. announces research collaboration with the SNU for gene editing based on CDVs

MDimune is named as one of the world's seven leading companies In exosome research

Aug 26, 2021  International Business Times discusses exosome research and introduces pace-setting companies. 

Find out more

Reyon and MDimune sign CDVs-mediated mRNA delivery partnership

Research collaboration with Navigo Proteins on Affilin®-mediated targeting of EVs

MDimune is named as one of the world's seven leading companies In exosome research

May 13, 2021  Reyon and MDimune has announced the signing of a partnership focused on mRNA delivery for antivirus vaccine and rare genetic disorder.  

Find out more

Research collaboration with Navigo Proteins on Affilin®-mediated targeting of EVs

Research collaboration with Navigo Proteins on Affilin®-mediated targeting of EVs

Research collaboration with Navigo Proteins on Affilin®-mediated targeting of EVs

May 11, 2021   Navigo Proteins and MDimune announced a technology collaboration to achieve tissue-targeting of extracellular vesicles (EVs), Affilin®-mediated delivery of CDVs specifically to solid tumor targets. 

Find out more

Partnership with Evercyte for developing tumor-targeting EVs

Research collaboration with Navigo Proteins on Affilin®-mediated targeting of EVs

Research collaboration with Navigo Proteins on Affilin®-mediated targeting of EVs

Apr 5, 2021 MDimune and Evercyte GmbH announced a strategic collaboration to develop tumor-targeted drug delivery by combining their technologies. 

Find out more

Service agreement with ExoNanoRNA to advance targeted drug delivery for cancer

Service agreement with ExoNanoRNA to advance targeted drug delivery for cancer

Service agreement with ExoNanoRNA to advance targeted drug delivery for cancer

Mar 15, 2021 ExonanoRNA and MDimune have entered into a service agreement to develop targeted siRNA therapy in oncology applications. 

Find out more

Korean researchers received MDimune’s 1st BioDrone® Award

Service agreement with ExoNanoRNA to advance targeted drug delivery for cancer

Service agreement with ExoNanoRNA to advance targeted drug delivery for cancer

Oct 30, 2020 MDimune announced the signing of research agreements with Pohang University of Science and Technology (POSTECH), Konkuk University, and Catholic University. 

Find out more

MDimune is selected by Lonza to the Startup Creasphere Program

Service agreement with ExoNanoRNA to advance targeted drug delivery for cancer

MDimune is selected by Lonza to the Startup Creasphere Program

Oct 28, 2020 Plug and Play, headquartered in Silicon Valley, California, announced that MDimune will be partnering with Lonza.  MDimune is among 11 Batch 5 startups to join the global startup incubation program ‘Startup Creasphere’.   

Find out more

Received “Best Cell Therapy Technology of the Year” award

Received “Best Cell Therapy Technology of the Year” award

MDimune is selected by Lonza to the Startup Creasphere Program

Oct 26, 2020 BioDrone® platform technology was awarded the “Best Cell Therapy Technology of the Year” at the annual Cell Therapy World Asia 2020 conference. 

Find out more

Collaboration with EV Experts at PMU

Received “Best Cell Therapy Technology of the Year” award

Collaboration with EV Experts at PMU

Apr 30, 2020 MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development.

Find out more

U.S. Patent Acquired

Received “Best Cell Therapy Technology of the Year” award

Collaboration with EV Experts at PMU

Apr 8, 2020 MDimune Received U.S. Patent on BioDrone® Technology.

Find out more

Copyright © 2022 BioDrone Therapeutics Inc. - All Rights Reserved.

  • Contact